Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor Antagonists.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
14 Aug 2024
Historique:
received: 11 07 2024
revised: 31 07 2024
accepted: 05 08 2024
medline: 1 9 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: epublish

Résumé

The adenosine A

Identifiants

pubmed: 39202926
pii: molecules29163847
doi: 10.3390/molecules29163847
pmc: PMC11357017
pii:
doi:

Substances chimiques

Quinazolines 0
Adenosine A2 Receptor Antagonists 0
Receptor, Adenosine A2A 0
Cyclic AMP E0399OZS9N

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Inserm
ID : recurring allocation
Organisme : Univ Lille
ID : recurring allocation

Références

Biochim Biophys Acta Rev Cancer. 2023 Nov;1878(6):189005
pubmed: 37913941
J Pharmacol Exp Ther. 2009 Jul;330(1):294-303
pubmed: 19332567
Medchemcomm. 2017 Aug 1;8(8):1659-1667
pubmed: 29250307
Expert Opin Investig Drugs. 2005 Jun;14(6):729-38
pubmed: 16004599
Med Res Rev. 2015 Jul;35(4):790-848
pubmed: 25821194
Bioorg Med Chem. 2009 Jan 1;17(1):119-32
pubmed: 19041249
Exp Neurol. 2007 Jan;203(1):241-5
pubmed: 17007839
Neuroscience. 2002;112(2):319-29
pubmed: 12044450
Brain. 2009 Jun;132(Pt 6):1480-95
pubmed: 19359287
Expert Opin Drug Discov. 2011 Jan;6(1):17-32
pubmed: 22328899
Pharmacol Rev. 2011 Mar;63(1):1-34
pubmed: 21303899
Angew Chem Int Ed Engl. 2020 Feb 10;59(7):2875-2880
pubmed: 31793137
J Med Chem. 2014 Jun 26;57(12):5141-56
pubmed: 24874647
J Med Chem. 2014 Oct 9;57(19):7955-70
pubmed: 25192394
Neuroscience. 2006 Nov 3;142(4):941-52
pubmed: 16938404
Br J Pharmacol. 2003 Apr;138(7):1207-9
pubmed: 12711619
Life Sci. 2001 Feb 9;68(12):1343-50
pubmed: 11388687
Eur J Med Chem. 2016 Aug 25;119:278-99
pubmed: 27235841
J Biomol Screen. 2009 Apr;14(4):360-70
pubmed: 19403919
J Med Chem. 2011 Feb 10;54(3):877-89
pubmed: 21214204
J Biomol Screen. 2010 Dec;15(10):1248-59
pubmed: 20974902
J Mol Neurosci. 2011 Mar;43(3):326-32
pubmed: 20838929
Neurobiol Aging. 2014 Sep;35(9):2079-90
pubmed: 24780254
J Med Chem. 2009 Jan 8;52(1):33-47
pubmed: 19072055
Eur J Med Chem. 2022 Nov 5;241:114620
pubmed: 35933788
Curr Med Chem. 2022;29(24):4138-4151
pubmed: 34844537
Neurochem Int. 2005 Oct;47(5):317-25
pubmed: 16011860
Prog Neurobiol. 2007 Apr;81(5-6):331-48
pubmed: 17303312
J Med Chem. 2020 Nov 12;63(21):12196-12212
pubmed: 32667814
Biochim Biophys Acta. 2011 May;1808(5):1290-308
pubmed: 21185259
Chem Rev. 2017 Jan 11;117(1):21-37
pubmed: 27333206
CNS Neurosci Ther. 2017 Apr;23(4):272-290
pubmed: 28317317
Mol Psychiatry. 2016 Jan;21(1):149
pubmed: 26216297
Adv Pharmacol. 2011;61:41-75
pubmed: 21586355
Assay Drug Dev Technol. 2010 Jun;8(3):356-66
pubmed: 20233092
J Neurol Sci. 2006 Oct 25;248(1-2):9-15
pubmed: 16806272
Front Immunol. 2022 Mar 21;13:837230
pubmed: 35386701
Int J Mol Sci. 2014 Jan 28;15(2):2024-52
pubmed: 24477263
Biochem Soc Trans. 2014 Apr;42(2):587-92
pubmed: 24646282
Biochem Pharmacol. 2010 Aug 15;80(4):506-11
pubmed: 20438717

Auteurs

Amélie Laversin (A)

Univ. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, F-59000 Lille, France.

Robin Dufossez (R)

Univ. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, F-59000 Lille, France.

Raphaël Bolteau (R)

Univ. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, F-59000 Lille, France.

Romain Duroux (R)

Univ. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, F-59000 Lille, France.

Séverine Ravez (S)

Univ. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, F-59000 Lille, France.

Sergio Hernandez-Tapia (S)

Univ. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, F-59000 Lille, France.

Martin Fossart (M)

Univ. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, F-59000 Lille, France.

Mathilde Coevoet (M)

Univ. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, F-59000 Lille, France.

Maxime Liberelle (M)

Univ. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, F-59000 Lille, France.

Saïd Yous (S)

Univ. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, F-59000 Lille, France.

Nicolas Lebègue (N)

Univ. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, F-59000 Lille, France.

Patricia Melnyk (P)

Univ. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, F-59000 Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH